Title : Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.

Pub. Date : 2019 Oct

PMID : 31385002






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sorafenib and CMG002 as single agents differentially inhibited or activated key enzymes in the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Sorafenib zinc fingers and homeoboxes 2 Homo sapiens
2 CONCLUSIONS: The combination of CMG002 and sorafenib significantly inhibited HCC cell proliferation and tumorigenesis by inhibiting the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Sorafenib zinc fingers and homeoboxes 2 Homo sapiens